Hoya invests in shape-changing, accommodating IOL

Article

Hoya has formed a strategic partnership with Adoptics of Switzerland by funding the development of a shape-changing accommodating intraocular lens (AIOL).

Hoya has formed a strategic partnership with Adoptics of Switzerland by funding the development of a shape-changing accommodating intraocular lens (AIOL).

Dr David Chang, a clinical professor of ophthalmology at the University of California, San Francisco, said: “This AIOL technology is based on a novel and clever concept that has the potential to produce a very powerful accommodative effect - something which remains the 'Holy Grail' of cataract and refractive surgery. ” Commenting on the investment, Tom Dunlap, President and CEO of Hoya Surgical Optics, stated: “Hoya recognizes the significant impact that the proprietary AIOL technology will have in addressing both the presbyopic and myopic challenges of patients with cataracts. We believe the shape-changing AIOL is the most efficient and consistent way to provide the power range necessary for true accommodation and to achieve spectacle-free vision for many patients. ”



Adoptics' founder and CEO, Dr Khalid Mentak, said: “This strategic partnership with HOYA will help us bring to market the first shape-changing accommodating IOL that closely mimics the mode of action of young crystalline lens.” Adoptics’ technology uses a proprietary fluid-based refraction system within an IOL to create significant changes in the refractive power of the human visual system. Unlike other presbyopia-correcting IOLs, the Adoptics lens does not require movement of the optic within the eye to change refractive power. The refractive surface of the IOL itself changes shape in response to movement of the ciliary muscles, the natural process of accommodation in the human eye.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.